** Shares in Bavarian Nordic BAVA.CO slump around 10%
after the Danish vaccine maker announced 2025 earnings guidance
below expectations
** The company sees 2025 revenue in the range of 5.7-6.7
billion Danish crowns vs an LSEG estimate of 6.42 billion and
expects EBITDA margin of 26%-30%
** It also flagged that revenue and EBITDA will vary
throughout the year, with first quarter of 2025 being light
** Kempen Life Sciences Research says the revenue guidance
is in line with consensus, but EBITDA outlook came in below
** The stock falls to its lowest since November and is
among top losers on Europe-wide STOXX 600 .STOXX index
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))